As a visionary leader, critical thinker, and entrepreneur, Jenna is committed to helping the medical community improve overall quality of life through the use of plant medicine through Medicinal Plant Research.
We Are Dedicated To Help Strengthen Canada’s National Pain Strategy And Change The Way We Deal With Chronic Pain With An Alternative To Pain Management Treatment — Medicinal Cannabis.
Indorgro™ Incorporated (“Indorgro”) is positioning itself to be at the forefront of medical cannabinoid research and development through the Centre for Medicinal Plant Health Research (CMPHR) at University of Guelph’s Ontario Agricultural College, School of Environmental Sciences. The CMPHR will advance our leading horticultural research program to guide Canada and the world into the next century of medicinal plant research creating a standardized pharmaceutical commodity. This is impact research that improves life.
• Build a dedicated closed-environment research space designed for the multi-disciplinary research and production of medicinal plants;
• Expand our critical mass of researchers, engineers, scientists;
• Acquire advanced research technologies in support of the highest quality plant research;
• Create dedicated cannabis research capacity to support the new and growing cannabis and cannabinoid research industry;
• Develop a body of research that focuses on genetics and breeding, propagation, production, harvesting, compositional analysis, postharvest storage, processing and using cannabis for human and animal health;
• Assist the cannabis industry with developing quality control standards for large-scale indoor/controlled environment production of recreational and medicinal cannabis;
• Provide industry training, technical support and technology transfer;
• Support governments with evidence-based scientific, peer reviewed research to assist with the development and evaluation of regulations and policy;
• Train the next generation of medicinal plant research and policy leaders through advanced experiential learning that shapes the future of medicinal plant research and its broad applications;
• Collaboratively support the growth of agri-food industry, medicinal plant production, and controlled environment food sustainability;
• Lead and influence social, economic, and health policies surrounding the vast medicinal plant industry through knowledge translation, vital partnerships, and quality production.
The Indorgro™ story started December 2011, when Indorgro Founder, Brad Rubin, was diagnosed with spinal stenosis. After 4 spinal surgeries, Brad was continuously prescribed opioid medications to treat his chronic neuropathic pain. These recurring prescriptions of powerful medications impacted him and his family’s livelihood immensely. Brad is dedicated to help strengthen Canada’s National Pain Strategy and change the way we deal with chronic pain with an alternative to pain management treatment — Medical Cannabis.
The Problem and Solution
Canadians are not strangers to the negative effects of opioids:
Brad’s story, however, took a positive turn when he discovered medical cannabis as an alternative to opioids to treat and manage his chronic pain symptoms. After 5 long years of being prescribed opioid medication, Brad transitioned to taking medical cannabis May 2017, and thereby significantly improving his quality of life, as well as his family’s. Footnote 6 Takakuwa KM, Hergenrather JY, Shofer FS, Schears RM (2019)The impact of medical cannabis on intermittent and chronic opioid users with back pain: how cannabis diminished prescription opioid usage, Cannabis and Cannabinoid Research 5:3, 263– 270, DOI: 10.1089/can.2019.0039. Please see Discussion on page 266.
Still, this solution came at an astronomical cost. Therefore, Brad decided to educate himself on growing his own supply of cannabis at the highest quality and lowest cost. As well as better understanding the Health Canada legal framework and regulations of the production of cannabis for your own medical purposes. Growing medicinal cannabis allowed Brad to find the right mixture of genetics that can be used to manage chronic pain symptoms. Please see Appendix A for Health Canada documents and additional academic journals that support medicinal cannabis as an effective pain management for various conditions.
An action plan for pain in Canada
Working together to better understand, prevent and, manage chronic pain: What We Heard
Chronic Pain in Canada: Laying a Foundation for Action
Section 2: Current approaches to diagnosing and managing chronic pain in Canada, Opioids and cannabis warrant special attention in the current Canadian context p13. Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the Cannabinoids: (PDF Version, 2.18MB, 266 pages) This document is a comprehensive review of the endocannabinoid system, how cannabinoids work and the evidence regarding health benefits. Section 4.0: Potential Therapeutic Uses p18Canadian Institutes of Health Research, Integrated Cannabis Research Strategy (ICRS):The overarching vision of the ICRS is that a well-coordinated series of activities can position Canada to be a world leader in developing the research capacity and amassing the research evidence needed to appropriately roll out policy and regulatory models for cannabis use .https://cihr-irsc.gc.ca/e/50932.html
The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research from the National Academies of Science Engineering and Medicine: This is a comprehensive review of the relevant research regarding the health effects of cannabis published since 1999. The report summarizes what is known about potential therapeutic effects of cannabis use.4 Therapeutic Effects of Cannabis and Cannabinoids: https://www.ncbi.nlm.nih.gov/books/NBK425767/Almog S, Aharon-Peretz J, Vulfsons S, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double- blinded, placebo-controlled trial. Eur J Pain. 2020;24:1505–1516. https://doi.org/10.1002/ejp.1605Takakuwa KM, Hergenrather JY, Shofer FS, Schears RM (2019) The impact of medical cannabis on intermittent and chronic opioid users with back pain: how cannabis diminished prescription opioid usage, Cannabis and Cannabinoid Research 5:3, 263– 270, DOI: 10.1089/can.2019.0039.Giorgi, V., Bongiovanni, S., Atzeni, F., Marotto, D., Salaffi, F. and Sarzi-Puttini, P., 2020. Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. Clin Exp Rheumatol, 38(123), pp.S53-S59.Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. J Am Med Assoc. 2015;313:2474–83.Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30–5.MacCallum C, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Int Med. 2018;49:12–9.Maurer, G.E., Mathews, N.M., Schleich, K.T., Slayman, T.G. and Marcussen, B.L., 2020. Understanding cannabis-based therapeutics in sports medicine. Sports health, 12(6), pp.540-546.Naccache, D. (2020). Cannabis alleviates neuropathic pain and reverses weight loss in diabetic neuropathic cachexia in a previous heroin abuser. Endocrinology, Diabetes & Metabolism Case Reports 2020, 20-0108, available from: https://doi.org/10.1530/EDM-20-0108Wiese B, Wilson-Poe AR. Emerging evidence for Cannabis’ role in opioid use disorder. Cannabis Cannabinoid Res. 2018;3:179–89.
Research by Jenna Rubin - Dec 31, 2020